<DOC>
	<DOCNO>NCT02456480</DOCNO>
	<brief_summary>To assess pharmacodynamics , safety/tolerability , efficacy omiganan patient mild moderate atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Pharmacodynamics Omiganan ( CLS001 ) Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . Male female subject mild moderate AD 18 65 year age , inclusive . 2 . AD diagnose physician / medical specialist ( intermittently ) present least 1 year 3 . Able participate willing give write informed consent comply study restriction . 1 . Have current / recurrent clinically significant skin condition treatment area AD . 2 . Any confirmed , active significant allergic reaction ( urticaria anaphylaxis ) include allergic reaction drug , multiple drug allergy ( ingredient ) emollient . 3 . Participation investigational drug device study within 3 month prior screen 4 time year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>